Bipartisan Solution Would Help Bring More Generics and Biosimilars to Market,
More Quickly — Reverse Big Pharma Attempts to Erode Skinny Labeling Pathway





 



ICYMI: SKINNY LABELS, BIG SAVINGS ACT INTRODUCED IN U.S. HOUSE

Bipartisan Solution Would Help Bring More Generics and Biosimilars to Market,
More Quickly — Reverse Big Pharma Attempts to Erode Skinny Labeling Pathway



In case you missed it, the bipartisan Skinny Labels, Big Savings Act
<[link removed]> was
introduced in the U.S. House this week by Representatives Ben Cline (R-VA-06)
and Zoe Lofgren (D-CA-18). A U.S. Senate companion bill (S.43
<[link removed]>) was introduced
in January of this year.



The longstanding practice known as skinny labeling has fostered competition
for decades by helping more affordable generic and biosimilar alternatives to
high-priced brand name drugs enter the market. Skinny labeling has generated
substantial savings for patients, taxpayers and the health care system.



But recent legal challenges from Big Pharma have weakened this framework,
creating additional opportunities for brand name drug companies to delay and
block more affordable alternatives from reaching American patients.



The Skinny Labels, Big Savings Act would help ensure the policy functions as
Congress intended, preserving legitimate patent rights while preventing
anti-competitive abuse of the system that keeps drug prices high.



Read more from the U.S. House sponsors’ press release
<[link removed]> below:



“’The Skinny Labels, Big Savings Act is a commonsense solution that protects
competition in the marketplace and ensures patients can get the medications
they need at a price they can afford. By reinforcing a key pathway that brings
safe, effective generics to market, we’re putting patients ahead of profit,’”
said Congressman Cline.



“The legislation strengthens protections for the use of ‘skinny labels,’ a
critical regulatory tool that allows generic and biosimilar manufacturers to
seek FDA approval for uses of a drug that are no longer protected by patents.
This pathway accelerates access to more affordable alternatives while
respecting valid intellectual property rights.”



“’For years, generic manufacturers have used skinny labels to lower drug costs
without infringing on brand-name patents,’ Cline continued. ‘But now, some
pharmaceutical companies are exploiting legal loopholes to sue generic
competitors and delay their entry into the market. Our bill stops that abuse
and restores fairness to the system.’



“The Skinny Labels Big Savings Act ensures that generic manufacturers who
obtain FDA approval for skinny label uses are not held liable for method-of-use
patent infringement when operating by federal law. It also provides clarity
that drugmakers can describe their generics as FDA-approved therapeutic
equivalents, provided that description aligns with FDA regulations.
Importantly, the bill reinforces that the use of skinny labels does not weaken
legitimate patent rights, but rather supports a system that was designed to
bring savings to patients, insurers, and taxpayers alike. The bill has earned
the backing of key patient and consumer advocacy organizations, including
Patients for Affordable Drugs NOW and the Campaign for Sustainable Rx Pricing.



“’We have a prescription drug affordability crisis in this country. Lawsuits
have eroded the ‘skinny label’ pathway and delayed the rollout of lower-cost
alternatives. With this bill, we are leveling the playing field and allowing
generic drug manufacturers to get their lifesaving prescription drugs to the
market faster, driving down costs for patients,’ said Rep. Zoe Lofgren.”



Read more about Big Pharma’s patent abuse HERE
<[link removed]>.



Read more on bipartisan, market-based solutions to hold Big Pharma accountable
HERE <[link removed]>.



###

































Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>